Reimagining the Healthcare System Innovation Ecosystem in Europe, Post-COVID
The COVID-19 pandemic transformed the pharma industry in the past two years, accelerating research and dialogue between stakeholders while unraveling significant deficiencies in the public healthcare infrastructure across the globe. At the tail-end of the pandemic, pioneers in healthcare took stock of the innovation, policies, and infrastructure at the Reuters event, Pharma 2021.
The first keynote panel discussion had industry experts look at the future of the healthcare innovation ecosystem in Europe. The panel comprised of 1. Nathalie Moll, Director General of EFPIA, European Federation of Pharmaceutical Industries and Associations 2. Jo De Cock, , Former Administrative General, INAMI, Institut national d'assurance maladie-invalidité, Belgium 3. Meindert Boysen, Director of National Institute of Health and Care Excellence, UK 4. Iskra Reic, Executive VP-AstraZeneca, Europe and Canada
Recounting their key learnings from the pandemic, the panelists shared optimism in incorporating collaboration and flexibility into building the future healthcare infrastructure.
The first keynote panel discussion had industry experts look at the future of the healthcare innovation ecosystem in Europe. The panel comprised of 1. Nathalie Moll, Director General of EFPIA, European Federation of Pharmaceutical Industries and Associations 2. Jo De Cock, , Former Administrative General, INAMI, Institut national d'assurance maladie-invalidité, Belgium 3. Meindert Boysen, Director of National Institute of Health and Care Excellence, UK 4. Iskra Reic, Executive VP-AstraZeneca, Europe and Canada
Recounting their key learnings from the pandemic, the panelists shared optimism in incorporating collaboration and flexibility into building the future healthcare infrastructure.